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ABSTRACT
Inflammatory bowel disease (IBD) is a medical condition characterized by chronic
inflammation of the intestinal epithelium. Krüppel-like factor 4 (KLF4), a zinc finger
transcription factor, is vital for maintaining intestinal epithelial homeostasis. KLF4
promotes differentiation of goblet cells that generate the protective mucus layer.
Reduced goblet cell number and defective mucus layer are associated with IBD. Shortchain fatty acids (SCFA) are known to play an important role in the maintenance of a
strong and healthy intestinal epithelial layer and also in goblet cell differentiation.
However, whether the positive effects of SCFAs on goblet cells are mediated, at least
partly, via upregulation of KLF4 is not known. Current studies were designed to
investigate if KLF4 expression is altered in inflammation and the role of SCFA in
modulating KLF4 expression. We utilized quantitative reverse transcriptase PCR and
Western blot, respectively, to measure the mRNA and protein levels of KLF4. Our
results showed a significant reduction in KLF4 expression in human intestinal Caco2
cells exposed to cytokines (TNF- α/IFN-γ 10 ng/ml, 24 h) and in a mouse model of
dextran sulfate sodium (DSS)-induced colitis (3% DSS 7 days). Of the 3 key SCFAs
(acetate, propionate, butyrate), incubation with propionate (2 mM 24 h) maximally
upregulated KLF4 mRNA and protein expression in Caco2 and colonic goblet cell-like
LS-174T cells. Also, propionate-induced KLF4 expression was abrogated in the
presence of the PPAR-g antagonist GW9662, while the PPAR-g agonist pioglitazone
mimicked and synergized the effects of propionate on KLF4 expression, suggesting the
role of PPAR-g in mediating propionate effects on KLF4. Propionate enhancement of
KLF4 could be of importance in correcting goblet cell hypoplasia in IBD.
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THE INTESTINAL EPITHELIUM AND INFLAMMATORY BOWEL DISEASE
INTRODUCTION
Structure of the Intestinal Epithelium
The GI tract is a series of hollow organs, reaching from the mouth to the anus,
which aids in transporting nutrients into the bloodstream throughout its length (1, 2). The
small intestine is approximately 6 meters in length and 2.5-3.0 cm in diameter, while the
colon is significantly shorter, only measuring roughly 1.5 meters in length, but has a
diameter of 6.0-7.5 cm (1). The lining of both the small and large intestine comprises of
intestinal epithelium, which is a single layer of columnar epithelial cells (3, 4). Although
the epithelium is only one layer thick, it is not a straight layer of cells. Instead, it consists
of inward invaginations called “crypts of Lieberkühn” (5). Intestinal stem cells (ISC)
reside at the base of these crypts and give rise to transient amplifying cells. They will
further differentiate into different cell types belonging to two lineages of cells, absorptive
and secretory cells (6). However, the intestinal epithelial cells (IEC) differ greatly in both
architectural structure and cellular composition between the two parts of the intestine. In
the small intestine, the epithelium has projections called villi that extend into the lumen.
The absorptive IECs then have numerous microvilli further protruding the lumen, which
greatly increases the mucosal surface area to improve nutrient absorption. These
projections are absent from the colon, giving rise to a flatter mucosal surface, which
prohibits potential damage caused by semi-solid stool transiting through the large
intestine.
Numerous different cell types are found in the intestinal epithelium, and each
differentiated cell type carries out specialized functions. The most prominent cell type is
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enterocytes (colonocytes in the large intestine), comprising approximately 80% of the
IECs (3, 4, 7). Enterocytes and microfold (M) cells belong to the absorptive lineage and
are responsible for water and nutrient absorption, and the uptake of luminal antigens to
the immune system, respectively. The secretory cells consist of enteroendocrine cells,
Paneth cells, goblet cells, and tuft cells. They produce and secrete gut hormones,
antimicrobial peptides, and mucins, respectively, while tuft cells play a key role in the
defense against helminths. The majority of all the cell types are found both in the small
and large intestine, including enterocytes, enteroendocrine cells, goblet cells, and tuft
cells. However, M cells and Paneth cells are unique to the small intestine.
Role of KLF4 in Goblet Cell Differentiation
The intestinal epithelium is a rapidly self-renewing tissue, and within 4-7 days the
epithelial layer is replaced, and the cells are shredded off into the lumen (4, 8, 9). To
maintain homeostasis, the events of cell proliferation, differentiation, migration, and
apoptosis are under tight regulation (6, 7). Several different studies have identified the
zinc finger containing transcription factor, Krüppel-like factor 4 (KLF4), to be involved in
the differentiation and migration of goblet cells in the intestinal epithelium (6, 9, 10).
KLF4 is normally expressed in post-mitotic, differentiated epithelial cells, and therefore
contributes to epithelial homeostasis (6, 9, 10). In 2002, Katz et al. provided evidence of
KLF4-null mice showing a reduction of 90% in the number of goblet cells compared to
the controls (7). Additionally, the same trend was seen in another in vivo study, where
KLF4 deletion resulted in overall altered goblet cell maturation and differentiation in the
colon (6). Combining the results of these two studies, it is apparent that KLF4 functions
as a colonic goblet cell-differentiation factor in vivo (6). Lastly, in a study using B-cell-
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specific Moloney murine leukemia virus integrin site 1 (BMI1), which is a known reserve
intestinal stem cell (rISC) marker, KLF4 deletion in BMI+ ISC mice resulted in
significantly lower levels of the goblet cell marker MUC2 compared to control mice (9),
again strengthening the evidence of KLF4’s role in goblet cell differentiation.
Role of KLF4 in Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD), including Chron’s disease (CD) and
ulcerative colitis (US), are characterized by inflammation of the gastrointestinal tract
(11). The two diseases exhibit recurring inflammation and intestinal epithelial cell
damage; however, their clinical symptoms are different. CD pathogenesis is linked to a
reduced number of antimicrobial peptides, autophagy, and changes to Paneth cells,
causing discontinuous inflammation, while UC patients suffer from goblet cell depletion,
which leads to reduced mucin secretion further causing increased intestinal permeability
(11). Even if the pathophysiology of IBD is not fully understood yet, the dysfunction of
the intestinal epithelial layer is an important part of the development of IBD. Dextran
sulfate sodium (DSS)-induced colitis is used to create an inflammatory condition in mice
(11). In a recent study, it was found that the steroid receptor coactivator 3 (SRC-3) plays
an important role in the development of severe DSS-induced colitis, as SCR-3-null mice
displayed colonic goblet cell dysfunction (11). Further, the disruption in goblet cell
function was linked to decreased levels of KLF4 in SCR-3-null mice.
Role of KLF4 in Colon Cancer
In the United States, colorectal cancer is the second most commonly diagnosed
type of cancer in both sexes, as well as the second leading cause of cancer deaths
(10). According to recent epidemiologic research, IBD has been proven to be
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associated with increased risks of colorectal cancer (12). In IBD patients, colitisassociated colorectal cancer (CAC) progresses in a stepwise fashion in a sequence
referred to as the inflammation-dysplasia-carcinoma pathway (12). Inflammationinduced environmental changes in the gut are thought to play important roles in the
induction of CAC. However, the exact mechanism for the development and progression
of CAC is unclear. Several factors have been identified to play important roles in the
formation of colorectal cancer like Wnt signaling, abnormality in the APC gene or betacatenin, and mutations in tumor suppressor genes (K-ras and p53) (10). Also, the
transcription factor KLF4 has been found to be downregulated in a variety of cancers,
including colorectal cancer (6, 10, 12). In an in vivo study done, using DSS and
azoxymethane (AOM) treatments to induce CAC in a murine mouse model, it was found
that KLF4-null mice developed significantly higher amounts of adenomatous polyps and
carcinomas in suit compared to the control mice (12). Further, they also found that
KLF4-null mice suffered shorter colon length, indicating increased inflammation severity.
This suggests that depletion of the transcription factor, KLF4, from the intestinal
epithelium, together with increased intestinal inflammation, could potentiate early
development of adenomas and carcinomas in KLF4-null mice treated AOM/DSS
compared to control mice.
Role of SCFAs in Goblet Cell Differentiation
SCFAs are produced in the intestines by anaerobic fermentation of nondigestible carbohydrates (13). SCFAs are important in terms of maintaining intestinal
homeostasis and IECs turnover, as well as providing sufficient energy for the epithelial
cells (13, 14). Further, SCFAs have been shown to promote mucus secretion, inhibit
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inflammation and tumor growth, and enhance cell differentiation (13). A study shows
that LS174-T cells, treated with SCFAs, influence MUC2 mRNA and protein levels by
increasing both (14). As MUC2 is an indicator for goblet cells, increased MUC2
expression would mean increased goblet cells, and thereby SCFAs affect intestinal
protection (15).
Hence, since KLF4 is required for goblet cell differentiation, and SCFAs have an
effect on goblet cell differentiation as well, we chose to look at whether SCFA effects on
goblet cell differentiation could occur via upregulation of KLF4.
MATERIAL AND METHODS
Chemicals and Antibodies
Acetate, propionate, butyrate, pioglitazone, TNF-α, IFN-γ were purchased from
Sigma Aldrich (St. Louis, MO), GW9662 was from Tocris Biosciences (Minneapolis,
MN). KLF4 antibody was from Thermo Fisher Scientific. All reagents were of analytical
or molecular biology grade.
Cell Culture
Human intestinal epithelial cell line Caco-2 was obtained from American Type
Culture Collection (ATCC, Manassas, CA). The Caco-2 cells were grown in cell culture
media MEM supplemented with 20% fetal bovine serum, 50 U/ml penicillin, and 50
µg/ml gentamicin. The cells were grown at 37°C in a 5% CO2-95% air environment.
LS174-T cells were also obtained from ATCC. LS174-T cells were grown in DMEM
media with 10% serum. Cells were seeded on 6, 12, or 24-well plates or 12-well
transwell insert plates and grown to confluency. Confluency was reached after 10 days
for LS174-T cells and 12 days for Caco-2 cells.
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Cell Treatments
For all treatments, model human intestinal Caco-2 and goblet-like LS174-T cells
were grown as confluent monolayers on 6-, 12- or 24-well plastic supports or 12-well
transwell inserts (for cytokine treatments from basolateral sides). Both cell lines were
treated with SCFAs (acetate, butyrate, or propionate, 2 mM, 24 h); propionate (1 mM, 2
mM, and 5 mM); cytokines (IFN-g 10 ng/ml and 30 ng/mg, TNF-a 10 ng/ml and 50
ng/ml, 24 h); PPAR-g antagonist GW9662 (5 µM) and PPAR-g pioglitazone (10 µM).
After the desired period of treatments, cells were harvested and stored at -80°C in lysis
buffer. RIPA lysis buffer (Santa Cruz Biotechnology) was used for samples prepared for
protein extraction, and RLT lysis buffer was used for samples prepared for quantitative
Real-Time RT-PCR.
Mice Tissue Samples
Colonic mucosal tissue lysates from normal mice and mice with dextran sulfate
sodium (DSS)-induced colitis were obtained from the Department of Gastroenterology
and Hepatology, University of Illinois at Chicago on a collaborative basis with the PI (Dr.
Borthakur) (16, 17).
RNA Extraction and Real-Time PCR
RNA was isolated from Caco-2 cells, LS174-T cells, or homogenized mouse
intestinal mucosal samples using the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. An equal amount of RNA (33.3 ng/µl) for each sample was
reverse-transcribed and amplified in a one-step reaction using the Brilliant SYBR Green
qRT-PCR Master Mix kit (Agilent). The recipe in Table 1 was used to prepare the
master mix for the real-time PCR. 2.25 µl of RNA and 7.75 µl of the master mix were
6

then pipetted into the corresponding low-profile PCR tubes (Bio-Rad). Human KLF4
gene was amplified with gene-specific primers (forward primer 5′CCACCTTCTTCACCCCTAGA-3′; reverse primer 5′CTTTGTGTAGGTTTTGCCGC-3′),
using human GAPDH (forward primer 5′-GAAATCCCATCACCATCTTCC-3′; reverse
primer 5′-AAATGAGCCCCAGCCTTCT-3′) as the internal control.
Reagent

Volume for 1 reaction

QRT

5 µl

Forward Primer

1 µl

Reverse Primer

1 µl

1:500 SYBR Dye

0.15 µl

Reverse Transcriptase

0.5 µl

DTT

0.1 µl

Table 1. Recipe for 1 Reaction for Real-Time PCR Master Mix
Western Blot Analysis
Lysates from whole cells (Caco-2 cells and LS174-T cells) and mouse colonic
mucosa were further prepared after being placed in RIPA buffer. Samples were
centrifuged for 10 minutes at 13,000 rpm and 4°C to remove cell material. The
supernatants were collected to further use for protein quantification using DC Protein
Assay (Bio-Rad) protocol (18). Protein samples (50 µg of total protein) were separated
using a 10% sodium dodecyl sulfate (SDS) gel and transferred onto a nitrocellulose
membrane. Membranes were blocked using 5% milk made with TBST and incubated
overnight at 4°C with the following primary antibodies: KLF4, PPAR-g, IFN-g, TNF-a,
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and internal controls GADPH or villin. The signals were detected using Enhanced
Chemiluminescence reagents (ECL Plus; GE Healthcare, London, UK). Quantification
of the bands was performed using ImageJ software (US National Institutes of Health)
and normalized using GAPDH and villin levels.
Statistical Analyses
Results are presented as means of 3-4 independent experiments, with error bars
represented by the standard error of the mean (SEM). Statistical analyses were
performed using GraphPad Prism (GraphPad Software). The comparison between
controls and treated groups was done using one-way ANOVA with Tukey’s test or
Student’s t-test. Statistical significance was considered for P £ 0.05.
RESULTS
KLF4 EXPRESSION IS DOWNREGULATED IN INTESTINAL INFLAMMATION
In the current studies, initially, we examined the effects inflammation had on the
protein levels of KLF4, a critical transcription factor involved in maintaining intestinal
epithelial homeostasis. In the in vitro model, intestinal epithelial Caco-2 cell monolayers
grown on transwell inserts were treated from the basolateral side with TNF-a and IFN-g,
two proinflammatory cytokines known to be elevated in IBD, for 24 h. In vivo, the protein
levels of KLF4 were measured in the colonic mucosa of control mice and mice with
DSS-colitis, a widely used animal model of IBD. KLF4 protein in cell lysates or mucosal
lysates was determined by SDS-PAGE and immunoblotting with KLF4 antibody.
GAPDH or villin was used as the loading control.
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Figure 1. KLF4 Protein Expression in DSS-Colitis Mouse Model and Caco-2 Cells
KLF4 protein expression is decreased in vivo in mouse model of DSS-colitis (A) and in
vitro in Caco-2 cells in response to treatments with TNF-α (B) and IFN-γ (C).
Representative blots of 3 independent experiments are shown.
EFFECTS OF SHORT-CHAIN FATTY ACIDS ON KLF4 EXPRESSION IN VITRO
SCFAs, primarily acetate, propionate, and butyrate produced by colonic bacterial
action on undigested dietary fiber, are known to augment goblet cell differentiation.
Since KLF4 is required for goblet cell differentiation, we sought to investigate whether
SCFA effects on goblet cells could be via upregulating KLF4. We used model human
intestinal cell line Caco-2 and a goblet-like cell line LS174 to examine the effects of
SCFAs on mRNA and protein levels of KLF4.
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Propionate Treatment Increases KLF4 mRNA Levels in Caco-2 Cells
Confluent cell monolayers of Caco-2 cell line were treated with 2 mM acetate,
propionate, or butyrate for 24 h. Total RNA extracted from the cells was used to
measure KLF4 mRNA levels by quantitative real-time (qRT)-PCR using human gene
specific primers and GAPDH as the internal control. As shown in Figure 2, propionate
significantly increased KLF4 mRNA compared to control, whereas acetate and butyrate
had no significant effect.

Relative KLF4 mRNA levels

2.5

*

2.0
1.5
1.0
0.5
0.0
Control

Acetate

Propionate

Butyrate

Treatments (2 mM, 24 h)

Figure 2. Propionate (2 mM, 24 h) Increases KLF4 mRNA in Caco-2 Cells (N=4,
*P<0.001)
Dose Response of Propionate on KLF4 mRNA in Caco-2 Cells
Dose response of propionate was determined by treating the cells with 1, 2, and
5 mM propionate for 24 h, and KLF4 mRNA levels were measured. A maximum
increase of KLF4 mRNA was observed with 2 mM propionate (Figure 3). Therefore, in
subsequent experiments on propionate effects, 2 mM propionate was used.
10

Figure 3. Dose Response of Propionate on KLF4 mRNA in Caco-2 Cells (N=4,
*P<0.05; **P<0.001)
Time-Course Effect of Propionate on KLF4 mRNA
The time-course of propionate effect on KLF4 mRNA was next measured by
treating the cells with 2 mM propionate for 8, 16, 24, and 48 h. Propionate treatment
increased KLF4 mRNA as early as after 8 h, however, maximum increase was
observed at 24 h, whereas propionate treatment for 48 h had no effect (Figure 4).
Therefore, in all subsequent experiments, 24 h time point was used for propionate
treatments.
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Figure 4. Time-Course Effect of Propionate on KLF4 mRNA in Caco-2 Cells (N=4,
*P<0.05; **P<0.001)
Propionate Increases KLF4 Protein Levels in Caco-2 and LS174-T Cells
Confluent monolayers of Caco-2 and LS174-T cells were treated with 2 mM
acetate, propionate, and butyrate for 24 h. Total proteins in the cell lysates were
separated by SDS-PAGE and probed with KLF4 antibody in immunoblotting. As shown
in Figure 5, propionate significantly increased KLF4 protein in Caco-2 cells, whereas
acetate and butyrate had no effect (5A). In LS174-T cells, both acetate and propionate
significantly increased KLF4 protein, with propionate showing maximum stimulatory
effect (5B).
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Figure 5. Propionate Increases KLF4 Protein Levels in (A) Caco-2 and (B) LS174-T
Cells (N=4, *P<0.05; **P<0.001)
ROLE OF PPAR-g IN MEDIATING PROPIONATE EFFECTS ON KLF4 EXPRESSION
Previous studies have shown the role of PPAR-γ in mediating SCFA-induced
modulation of gene expression (19). Therefore, to elucidate the mechanisms of
propionate effects on KLF4 expression, we examined the potential role of PPAR-γ by
treating the cells with PPAR-γ agonist and antagonist ± propionate and measuring KLF4
mRNA and protein levels.
Effect of PPAR-γ Agonist Pioglitazone on KLF4 mRNA
Caco-2 and LS174-T cells were incubated with pioglitazone (10 µM) ± propionate
(2 mM) for 24 h and KLF4 mRNA was measured. In both cell lines, Caco-2 (A) and
LS174-T (B), pioglitazone alone significantly increased KLF4 mRNA, whereas
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synergistic/additive effects on KLF4 mRNA were found when cells were treated with
both pioglitazone and propionate (Figure 6).

Figure 6. PPAR-γ Agonist Pioglitazone Effect on Caco-2 and LS174-T Cells
PPAR-γ agonist pioglitazone increases KLF4 mRNA and shows synergistic/additive
effects with propionate in (A) Caco-2 and (B) LS174-T cells (N=3, *P<0.001)
Effect of PPAR-γ Antagonist GW9662 on KLF4 mRNA
Caco-2 and LS174-T cells were incubated with GW9662 (5 µM) ± propionate (2
mM) for 24 h and KLF4 mRNA was measured. Results are shown in Figure 7. In both
the cell lines, Caco-2 (A) and LS174-T (B), GW9662 alone had no effect on KLF4
mRNA. Propionate alone significantly increased KLF4 mRNA, which, however, was
abrogated in presence of GW9662. Thus, these studies with PPAR-γ agonist and
antagonist suggest that propionate effects on KLF4 could be mediated via PPAR-γ.
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Figure 7. PPAR-γ Antagonist GW9662 Abrogates the Stimulatory Effects of
Propionate on KLF4 mRNA in (A) Caco-2 and (B) LS174-T Cells (N=3, *P<0.001)
Effect of PPAR-γ Agonist Pioglitazone on KLF4 Protein Levels in Caco-2 Cells
Caco-2 cells were incubated with pioglitazone (10 µM) ± propionate (2 mM) for
24 h. Cell lysates were prepared and KLF4 protein levels were measured by Western
blot. Results are shown in Figure 8. Pioglitazone alone or propionate alone significantly
increased KLF4 protein, whereas synergistic/additive effects on KLF4 protein were
found when cells were treated with both pioglitazone and propionate. All these results
taken together suggest a role of PPAR-γ in mediating the effects of propionate on KLF4
expression.
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Figure 8. PPAR-γ Agonist Pioglitazone Increases KLF4 Protein and Shows
Synergistic/Additive Effects with Propionate in Caco-2 Cells (N=3, *P<0.05;
**P<0.001)
DISCUSSION
In recent years, there has been mounting evidence of the role of gut microbiota
and the metabolites, more specifically the SCFA, in maintaining intestinal epithelial
homeostasis via varied mechanisms. Both propionate and butyrate, two of the most
common SCFAs, are produced from carbohydrate fermentation and amino acid
fermentation by different bacterial species. It is known that propionate plays an
important role in maintaining homeostasis in the intestinal epithelium, as the SCFA is
used as an energy source in intestinal cells and aids in inflammatory responses (14, 20,
21). Therefore, when dysbiosis in the gut microbiota arises, these SCFAs cannot be
produced in the same manner, which can cause the intestinal epithelial layer to be
16

damaged. Such disruption can further cause inflammation of the intestinal epithelium
and develop IBD. The SCFA propionate, together with other SCFAs, are considered a
promising supplementary treatment for IBD (14). Since IBD is a very individualized
disease, with several different side effects, it is difficult to create subtype-specific
treatments. Several studies have shown that the use of a SCFAs enema mix has had
little effect on both UC and CD patients and animal subjects (14). However, when
administering oral treatment containing SCFA-producing bacteria to DSS-colitis mice,
the colonic mucosal damage was decreased. This suggests that SCFAs administered
by themselves are not as effective as treatments with SCFA-producing bacteria.
Therefore, the use of SCFA-producing pre- or probiotics could potentially restore the
intestinal mucosa homeostasis in IBD suffering patients.
KLF4 is a zinc finger transcription factor, predominantly expressed in
differentiated epithelial cells of the small intestine and colon. KLF4 plays multiple roles
in the human body, but recent studies have found the transcription factor to play an
important role in regulating intestinal epithelial cell homeostasis (6). Mice with intestine
specific deletion of KLF4 exhibited an increase in epithelial proliferation, decreased
differentiation, and a reduction in goblet cell number (9, 10, 12). On the other hand,
augmenting KLF4 expression has been shown to promote goblet cell differentiation and
alleviate DSS-induced colitis (11). Goblet cell hypoplasia and defective synthesis of
protective mucus layer are associated with IBD. Therefore, the agents that upregulate
KLF4 and/or counteract downregulation of KLF4 in inflammation could correct goblet
cell hypoplasia. In this regard, SCFAs are known to enhance epithelial protection via
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stimulating mucus synthesis by goblet cells but their effects on KLF4 expression are not
studied in detail.
In this study, we first examined the effects of the cytokines TNF-α and IFN-γ,
known to be elevated in IBD, on KLF4 expression in vitro in Caco-2 cells and also
measured KLF4 protein levels in the colonic mucosa of normal versus DSS-colitis mice.
In both models, we observed extensive downregulation of KLF4. Indeed, KLF4 was
almost diminished in response to DSS-colitis. Secondly, we have observed the SCFA
propionate, an important gut microbiota metabolite, as a potential therapeutic agent
showing a stimulatory effect on KLF4 expression in both Caco-2 cells and LS174-T
cells. Further, we have performed mechanistic studies to show that propionate-induced
KLF4 expression was abrogated in the presence of the PPAR-g-specific antagonist
GW9662, while the PPAR-g-specific agonist pioglitazone mimicked and synergized the
effects of propionate on KLF4 expression. This suggests that the propionate-induced
KLF4 expression could occur via a PPAR-g-dependent mechanism. This, in turn, could
improve the differentiation of goblet cells, that, via secretion of mucins, exert protective
effects on intestinal epithelium. However, these preliminary studies need to be further
supported by determining in vitro and in vivo that propionate treatments could
counteract inflammation-induced downregulation of KLF4 expression. Further, to define
novel therapeutic targets for IBD, detailed mechanistic studies are needed to establish
the link between KLF4 and goblet cell differentiation and function.
CONCLUSION
The results of this study show that the SCFA propionate exerts a stimulatory
effect on KLF4 expression in intestinal epithelial cells. Our results also show
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downregulation of KLF4 expression in intestinal inflammation. In view of the known role
of KLF4 in health and disease, more particularly the experimental evidence from
multiple investigators showing its critical role in maintaining intestinal epithelial
homeostasis via governing goblet cell differentiation, propionate enhancement of KLF4
could be of importance in correcting the goblet cell hypoplasia in IBD. However, a more
detailed knowledge of the mechanism and interplay between the SCFA propionate and
the zinc-finger containing transcription factor KLF4 in the pathophysiology of IBD is
necessary to define novel therapeutic targets to develop superior treatment modalities
for IBD.
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